Manufacturer
MSD
Contents
Ezetimibe 10 mg, atorvastatin 20 mg.
Indication
Treatment of hypercholesterolaemia
Instruction
May be taken with or without food.
Drug interaction
Atorvastatin: Increased plasma conc w/ CYP3A4 inhibitors. Increased AUC w/ clarithromycin, PIs (eg, telaprevir, tipranavir/ritonavir, lopinavir/ritonavir, saquinavir/ritonavir, darunavir/ritonavir, fosamprenavir or fosamprenavir/ritonavir). Increased plasma conc w/ excessive grapefruit consumption (>1.2 L/day). Increased bioavailability w/ organic anion-transporting polypeptide 1B1 transporter (eg, cyclosporine). Increased plasma conc & risk of myopathy w/ breast cancer resistant protein inhibitors (eg, elbasvir & grazoprevir. Decreased plasma conc w/ CYP3A4 inducers (eg, efavirenz, rifampin), colestipol. Increased digoxin conc. Increased AUC values for norethindrone and ethinyl estradiol. May enhance the risk of skeletal muscle effects w/ niacin. Cases of myopathy w/ colchicine. Ezetimibe: Decreased plasma conc w/ oral antacid susp containing Mg & Al hydroxide. Decreased mean AUC w/ cholestyramine. Increased risk of myopathy/rhabdomyolysis w/ gemfibrozil & fusidic acid. Risk of myopathy w/ fenofibrate.
Malaysia
